CA3034484A1 - Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts - Google Patents

Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts Download PDF

Info

Publication number
CA3034484A1
CA3034484A1 CA3034484A CA3034484A CA3034484A1 CA 3034484 A1 CA3034484 A1 CA 3034484A1 CA 3034484 A CA3034484 A CA 3034484A CA 3034484 A CA3034484 A CA 3034484A CA 3034484 A1 CA3034484 A1 CA 3034484A1
Authority
CA
Canada
Prior art keywords
cells
antibody
protein
expression
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3034484A
Other languages
English (en)
French (fr)
Inventor
Jay M. Short
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioatla Inc
Original Assignee
Bioatla Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioatla Inc filed Critical Bioatla Inc
Publication of CA3034484A1 publication Critical patent/CA3034484A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Ecology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA3034484A 2009-07-17 2010-07-16 Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts Pending CA3034484A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27116809P 2009-07-17 2009-07-17
CA2768247A CA2768247C (en) 2009-07-17 2010-07-16 Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
US62/271,168 2015-12-22

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2768247A Division CA2768247C (en) 2009-07-17 2010-07-16 Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts

Publications (1)

Publication Number Publication Date
CA3034484A1 true CA3034484A1 (en) 2011-01-20

Family

ID=43450243

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2768247A Active CA2768247C (en) 2009-07-17 2010-07-16 Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
CA3034484A Pending CA3034484A1 (en) 2009-07-17 2010-07-16 Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2768247A Active CA2768247C (en) 2009-07-17 2010-07-16 Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts

Country Status (18)

Country Link
US (6) US8859467B2 (cg-RX-API-DMAC7.html)
EP (6) EP3636759B1 (cg-RX-API-DMAC7.html)
JP (3) JP6193570B2 (cg-RX-API-DMAC7.html)
KR (5) KR20210013294A (cg-RX-API-DMAC7.html)
CN (2) CN107090031A (cg-RX-API-DMAC7.html)
AU (5) AU2010273974B2 (cg-RX-API-DMAC7.html)
BR (2) BR112012001171B1 (cg-RX-API-DMAC7.html)
CA (2) CA2768247C (cg-RX-API-DMAC7.html)
DK (5) DK2907873T3 (cg-RX-API-DMAC7.html)
ES (3) ES2652340T3 (cg-RX-API-DMAC7.html)
HU (1) HUE029328T2 (cg-RX-API-DMAC7.html)
IN (1) IN2012DN00737A (cg-RX-API-DMAC7.html)
MX (3) MX347654B (cg-RX-API-DMAC7.html)
MY (2) MY173037A (cg-RX-API-DMAC7.html)
PL (2) PL3042957T3 (cg-RX-API-DMAC7.html)
PT (1) PT3042957T (cg-RX-API-DMAC7.html)
SG (3) SG10201505075TA (cg-RX-API-DMAC7.html)
WO (1) WO2011009058A2 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201505075TA (en) * 2009-07-17 2015-07-30 Bioatla Llc Simultaneous, Integrated Selection And Evolution Of Antibody/Protein Performance And Expression In Production Hosts
WO2011109726A2 (en) * 2010-03-05 2011-09-09 Bioatla Llc Homologous multi-specific antibodies
EP3435087B1 (en) 2010-07-16 2023-11-08 BioAtla, Inc. Novel methods of protein evolution
AU2015242961B2 (en) * 2010-07-16 2017-03-02 Bioatla, Llc Novel methods of protein evolution
JP6121904B2 (ja) 2010-09-08 2017-04-26 ハロザイム インコーポレイテッド 条件的活性治療用タンパク質を評価および同定する、または発展させる方法
EP2773964A4 (en) * 2011-11-03 2015-06-24 Stc Biolog Inc METHOD FOR DETERMINING THE PHARMACOLOGICAL PROPERTIES OF RECOMBINANT PROTEINS
US10156574B2 (en) 2013-04-29 2018-12-18 Adimab, Llc Polyspecificity reagents, methods for their preparation and use
US11293929B2 (en) * 2014-01-07 2022-04-05 Bioatla, Inc. Proteins targeting orthologs
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
CN106459960A (zh) * 2014-05-13 2017-02-22 生物蛋白有限公司 条件活性生物蛋白
US20180180626A1 (en) * 2014-07-01 2018-06-28 Stc Biologics, Inc. A method for development of recombinant proteins with fingerprint like similarity to the reference product
KR102818922B1 (ko) 2014-08-28 2025-06-11 바이오아트라, 인코퍼레이티드 변형된 t 세포에 대한 조건부 활성 키메라 항원 수용체
CA2959786A1 (en) 2014-09-03 2016-03-10 Bioatla, Llc Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
SG11201705988UA (en) 2015-02-24 2017-08-30 Bioatla Llc Conditionally active biological proteins
JP6959912B2 (ja) * 2015-09-23 2021-11-05 ジェネンテック， インコーポレイテッド 抗ｖｅｇｆ抗体の最適化変異体
US11472876B2 (en) 2015-11-02 2022-10-18 Bioatla, Inc. Conditionally active polypeptides
WO2017197234A1 (en) 2016-05-13 2017-11-16 Bioatla, Llc Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
PE20200757A1 (es) 2017-07-11 2020-07-27 Compass Therapeutics Llc Anticuerpos agonistas que se unen a cd137 humano y sus usos
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
AU2019379576A1 (en) 2018-11-13 2021-06-03 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
EP3955960B1 (en) 2019-04-18 2025-01-15 Bristol-Myers Squibb Company Ipilimumab variants with enhanced specificity for binding at low ph
WO2020227515A1 (en) 2019-05-07 2020-11-12 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
CN111048154B (zh) * 2019-12-10 2023-06-06 上海药明生物技术有限公司 一种抗体表位作图的方法
CN111462815B (zh) * 2020-03-27 2023-05-02 上海祥耀生物科技有限责任公司 一种抗体库的构建方法及装置
US11506060B1 (en) * 2021-07-15 2022-11-22 Honeywell International Inc. Radial turbine rotor for gas turbine engine
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
US20250295809A1 (en) 2022-05-13 2025-09-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
TW202435912A (zh) 2022-08-03 2024-09-16 美商航海家醫療公司 用於穿過血腦屏障之組合物及方法
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4957858A (en) 1986-04-16 1990-09-18 The Salk Instute For Biological Studies Replicative RNA reporter systems
US4883750A (en) 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
AU622104B2 (en) 1987-03-11 1992-04-02 Sangtec Molecular Diagnostics Ab Method of assaying of nucleic acids, a reagent combination and kit therefore
CA1323293C (en) 1987-12-11 1993-10-19 Keith C. Backman Assay using template-dependent nucleic acid probe reorganization
JP2846018B2 (ja) 1988-01-21 1999-01-13 ジェネンテク，インコーポレイテッド 核酸配列の増幅および検出
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
AU623642B2 (en) 1988-03-24 1992-05-21 University Of Iowa Research Foundation, The Catalytic hybridization systems for the detection of nucleic acid sequences based on their activity as cofactors in catalytic reactions in which a complementary labeled nucleic acid probe is cleaved
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
ES2198416T3 (es) 1992-11-24 2004-02-01 G.D. SEARLE & CO. Polipeptidos de mutacion multiples de interleuquina-3 (il-3).
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US6764835B2 (en) 1995-12-07 2004-07-20 Diversa Corporation Saturation mutageneis in directed evolution
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
US20030219752A1 (en) * 1995-12-07 2003-11-27 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
US6238884B1 (en) 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
US8137906B2 (en) 1999-06-07 2012-03-20 Sloning Biotechnology Gmbh Method for the synthesis of DNA fragments
US7033781B1 (en) 1999-09-29 2006-04-25 Diversa Corporation Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
HUP0303171A2 (hu) 2001-02-19 2003-12-29 Merck Patent Gmbh Csökkentett immunogenitású mesterséges fehérjék
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
EP1421203A4 (en) * 2001-05-17 2005-06-01 Diversa Corp NEW ANTIGEN-BINDING MOLECULES FOR THERAPEUTIC, DIAGNOSTIC, PROPHYLACTIC, ENZYMATIC, INDUSTRIAL AND AGRICULTURAL APPLICATIONS AND METHOD FOR THE PRODUCTION AND SCREENING THEREOF
US7647184B2 (en) * 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
CN1836041A (zh) * 2003-06-27 2006-09-20 比奥伦公司 浏览突变
GB0520169D0 (en) * 2005-10-04 2005-11-09 Celltech R&D Ltd Biological products
WO2007047578A2 (en) * 2005-10-14 2007-04-26 Medimmune, Inc. Cell display of antibody libraries
WO2008118476A2 (en) * 2007-03-26 2008-10-02 Codon Devices, Inc. Cell surface display, screening and production of proteins of interest
WO2009059235A2 (en) 2007-11-01 2009-05-07 Facet Biotech Corporation Immunoglobulin display vectors
CN101878303B (zh) 2007-11-02 2014-04-30 斯克利普斯研究院 使用包含非天然氨基酸的蛋白质进行定向进化
US8312249B1 (en) 2008-10-10 2012-11-13 Apple Inc. Dynamic trampoline and structured code generation in a signed code environment
SG10201505075TA (en) * 2009-07-17 2015-07-30 Bioatla Llc Simultaneous, Integrated Selection And Evolution Of Antibody/Protein Performance And Expression In Production Hosts
FR2957821B1 (fr) 2010-03-24 2014-08-29 Inst Francais Du Petrole Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives

Also Published As

Publication number Publication date
KR20210013294A (ko) 2021-02-03
MX392642B (es) 2025-03-19
AU2019203813B2 (en) 2021-03-11
AU2021203220B2 (en) 2023-05-04
ES2701931T3 (es) 2019-02-26
AU2010273974B2 (en) 2016-01-14
AU2015243076A1 (en) 2015-11-05
US20150024944A1 (en) 2015-01-22
US10106788B2 (en) 2018-10-23
CA2768247A1 (en) 2011-01-20
US20240263354A1 (en) 2024-08-08
ES2581318T3 (es) 2016-09-05
US20180371452A1 (en) 2018-12-27
US10920216B2 (en) 2021-02-16
EP2454376A4 (en) 2013-07-10
US20120165201A1 (en) 2012-06-28
EP2907873B1 (en) 2016-04-06
WO2011009058A3 (en) 2011-04-14
EP2454376B1 (en) 2015-12-02
EP3406717B1 (en) 2019-12-11
AU2017203243B2 (en) 2019-07-11
BR122015012748A2 (pt) 2020-01-07
AU2010273974A8 (en) 2012-02-23
PL3042957T3 (pl) 2018-03-30
SG10201505075TA (en) 2015-07-30
KR101823872B1 (ko) 2018-01-31
HUE029328T2 (en) 2017-02-28
PT3042957T (pt) 2017-12-21
EP2454376A2 (en) 2012-05-23
EP3636759A1 (en) 2020-04-15
JP2015211672A (ja) 2015-11-26
US11976381B2 (en) 2024-05-07
IN2012DN00737A (cg-RX-API-DMAC7.html) 2015-06-19
DK3156485T3 (en) 2019-01-07
EP3042957B1 (en) 2017-09-13
JP6681131B2 (ja) 2020-04-15
BR112012001171B1 (pt) 2021-09-21
EP3042957A1 (en) 2016-07-13
ES2652340T3 (es) 2018-02-01
JP2012533307A (ja) 2012-12-27
DK3042957T3 (en) 2018-01-02
EP2907873A1 (en) 2015-08-19
KR20220002712A (ko) 2022-01-06
MX347654B (es) 2017-05-05
PL2907873T3 (pl) 2016-10-31
MX2012000803A (es) 2012-06-01
EP3156485B1 (en) 2018-09-12
DK2907873T3 (en) 2016-06-13
HK1210623A1 (en) 2016-04-29
US8859467B2 (en) 2014-10-14
CN102625848A (zh) 2012-08-01
KR20120069664A (ko) 2012-06-28
AU2010273974A1 (en) 2012-02-09
AU2019203813A1 (en) 2019-06-20
EP3406717A1 (en) 2018-11-28
KR20190017070A (ko) 2019-02-19
CN107090031A (zh) 2017-08-25
KR20180010347A (ko) 2018-01-30
DK3636759T3 (da) 2023-10-23
SG177687A1 (en) 2012-02-28
CA2768247C (en) 2019-04-09
DK3406717T3 (da) 2020-03-16
WO2011009058A2 (en) 2011-01-20
US20210207129A1 (en) 2021-07-08
EP3156485A1 (en) 2017-04-19
AU2021203220A1 (en) 2021-06-10
JP6193570B2 (ja) 2017-09-13
BR112012001171A2 (pt) 2017-06-13
JP6193913B2 (ja) 2017-09-06
MY173037A (en) 2019-12-20
AU2015243076B2 (en) 2017-02-23
US20120245036A1 (en) 2012-09-27
US10047357B2 (en) 2018-08-14
SG10201700096VA (en) 2017-02-27
MY160472A (en) 2017-03-15
AU2017203243A1 (en) 2017-06-08
JP2017205110A (ja) 2017-11-24
EP3636759B1 (en) 2023-10-11

Similar Documents

Publication Publication Date Title
AU2021203220B2 (en) Simultaneous, Integrated Selection and Evolution of Antibody/Protein Performance and Expression in Production Hosts
US11639365B2 (en) Methods of protein evolution
HK40026409A (en) Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
HK1236221A1 (en) Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
HK1236221B (en) Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
HK1230231A1 (en) Simultaneous, integrated selection and evolution of human protein performance and expression in production hosts
HK1210623B (en) Simulataneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
HK1230231B (en) Simultaneous, integrated selection and evolution of human protein performance and expression in production hosts
AU2015242961A1 (en) Novel methods of protein evolution

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190221

EEER Examination request

Effective date: 20190221

EEER Examination request

Effective date: 20190221

EEER Examination request

Effective date: 20190221